386 related articles for article (PubMed ID: 34461271)
1. Rethinking mechanisms of neurotoxicity with BCMA directed therapy.
Mohyuddin GR; Banerjee R; Alam Z; Berger KE; Chakraborty R
Crit Rev Oncol Hematol; 2021 Oct; 166():103453. PubMed ID: 34461271
[TBL] [Abstract][Full Text] [Related]
2. The emergence of b-cell maturation antigen (BCMA) targeting immunotherapy in multiple myeloma.
Davis JA; Shockley A; Hashmi H
J Oncol Pharm Pract; 2022 Jun; 28(4):960-968. PubMed ID: 35006032
[TBL] [Abstract][Full Text] [Related]
3. Focus on monoclonal antibodies targeting B-cell maturation antigen (BCMA) in multiple myeloma: update 2021.
Demel I; Bago JR; Hajek R; Jelinek T
Br J Haematol; 2021 May; 193(4):705-722. PubMed ID: 33216972
[TBL] [Abstract][Full Text] [Related]
4. Targeting B Cell Maturation Antigen (BCMA) in Multiple Myeloma: Potential Uses of BCMA-Based Immunotherapy.
Cho SF; Anderson KC; Tai YT
Front Immunol; 2018; 9():1821. PubMed ID: 30147690
[TBL] [Abstract][Full Text] [Related]
5. An update on B-cell maturation antigen-targeted therapies in Multiple Myeloma.
Martino M; Paviglianiti A
Expert Opin Biol Ther; 2021 Aug; 21(8):1025-1034. PubMed ID: 33412948
[No Abstract] [Full Text] [Related]
6. BCMA-targeted immunotherapy for multiple myeloma.
Yu B; Jiang T; Liu D
J Hematol Oncol; 2020 Sep; 13(1):125. PubMed ID: 32943087
[TBL] [Abstract][Full Text] [Related]
7. B-cell maturation antigen (BCMA) in multiple myeloma: rationale for targeting and current therapeutic approaches.
Shah N; Chari A; Scott E; Mezzi K; Usmani SZ
Leukemia; 2020 Apr; 34(4):985-1005. PubMed ID: 32055000
[TBL] [Abstract][Full Text] [Related]
8. B-Cell Maturation Antigen (BCMA) as a Target for New Drug Development in Relapsed and/or Refractory Multiple Myeloma.
Abramson HN
Int J Mol Sci; 2020 Jul; 21(15):. PubMed ID: 32707894
[TBL] [Abstract][Full Text] [Related]
9. BCMA-targeted therapies for multiple myeloma: strategies to maximize efficacy and minimize adverse events.
Watson E; Djebbari F; Rampotas A; Ramasamy K
Expert Rev Hematol; 2022 Jun; 15(6):503-517. PubMed ID: 35633050
[TBL] [Abstract][Full Text] [Related]
10. Innovative Anti-CD38 and Anti-BCMA Targeted Therapies in Multiple Myeloma: Mechanisms of Action and Resistance.
De Novellis D; Fontana R; Giudice V; Serio B; Selleri C
Int J Mol Sci; 2022 Dec; 24(1):. PubMed ID: 36614086
[TBL] [Abstract][Full Text] [Related]
11. Targeting BCMA to Treat Multiple Myeloma: Updates From the 2021 ASH Annual Meeting.
Guo R; Lu W; Zhang Y; Cao X; Jin X; Zhao M
Front Immunol; 2022; 13():839097. PubMed ID: 35320942
[TBL] [Abstract][Full Text] [Related]
12. BCMA-directed therapy, new treatments in the myeloma toolbox, and how to use them.
Rees MJ; Kumar S
Leuk Lymphoma; 2024 Mar; 65(3):287-300. PubMed ID: 38354090
[TBL] [Abstract][Full Text] [Related]
13. B cell maturation antigen (BCMA)-based immunotherapy for multiple myeloma.
Tai YT; Anderson KC
Expert Opin Biol Ther; 2019 Nov; 19(11):1143-1156. PubMed ID: 31277554
[No Abstract] [Full Text] [Related]
14. Targeting BCMA in Multiple Myeloma.
Tan CR; Shah UA
Curr Hematol Malig Rep; 2021 Oct; 16(5):367-383. PubMed ID: 34432234
[TBL] [Abstract][Full Text] [Related]
15. An anti-B cell maturation antigen bispecific antibody for multiple myeloma.
Ramadoss NS; Schulman AD; Choi SH; Rodgers DT; Kazane SA; Kim CH; Lawson BR; Young TS
J Am Chem Soc; 2015 Apr; 137(16):5288-91. PubMed ID: 25826669
[TBL] [Abstract][Full Text] [Related]
16. New and emerging pharmacotherapies for the management of multiple myeloma.
Moore DC; Oxencis CJ; Shank BR
Am J Health Syst Pharm; 2022 Jul; 79(14):1137-1145. PubMed ID: 35333922
[TBL] [Abstract][Full Text] [Related]
17. Preclinical Efficacy and Safety Comparison of CD3 Bispecific and ADC Modalities Targeting BCMA for the Treatment of Multiple Myeloma.
Panowski SH; Kuo TC; Zhang Y; Chen A; Geng T; Aschenbrenner L; Kamperschroer C; Pascua E; Chen W; Delaria K; Farias S; Bateman M; Dushin RG; Chin SM; Van Blarcom TJ; Yeung YA; Lindquist KC; Chunyk AG; Kuang B; Han B; Mirsky M; Pardo I; Buetow B; Martin TG; Wolf JL; Shelton D; Rajpal A; Strop P; Chaparro-Riggers J; Sasu BJ
Mol Cancer Ther; 2019 Nov; 18(11):2008-2020. PubMed ID: 31434693
[TBL] [Abstract][Full Text] [Related]
18. Chimeric antigen receptor T-cells, bispecific antibodies, and antibody-drug conjugates for multiple myeloma: An update.
Lakshman A; Kumar SK
Am J Hematol; 2022 Jan; 97(1):99-118. PubMed ID: 34661922
[TBL] [Abstract][Full Text] [Related]
19. B-cell maturation antigen (BCMA) in multiple myeloma: the new frontier of targeted therapies.
Sanchez L; Dardac A; Madduri D; Richard S; Richter J
Ther Adv Hematol; 2021; 12():2040620721989585. PubMed ID: 33796236
[TBL] [Abstract][Full Text] [Related]
20. BCMA loss in the epoch of novel immunotherapy for multiple myeloma: from biology to clinical practice.
Zhou X; Rasche L; Kortüm KM; Mersi J; Einsele H
Haematologica; 2023 Apr; 108(4):958-968. PubMed ID: 36263838
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
